India's income tax department is conducting searches at Mankind Pharma Ltd's office in New Delhi, a government source told Reuters on Thursday, days after the condom maker's successful public listing on domestic stock exchanges.
The company's shares fell as much as 5.5% on the news.
Further details were not immediately available. Mankind Pharma and the IT department did not immediately respond to Reuters' requests for comment.
Mankind Pharma shares debuted on the Indian stock exchange on Tuesday and surged about 32%, valuing the maker of Manforce condoms at 569.76 billion rupees ($6.97 billion), in a rare instance of a successful domestic public listing this year.
The stock was last trading down 3.5% at 1,335 rupees on Thursday but was still well above its initial public offering offer (IPO) price of 1,080 rupees.
Mankind Pharma says its Manforce is the top-selling male condom brand in India, where it competes with Reckitt Benckiser Group's Durex and TTK Group's Skore.
Also Read
($1 = 81.7800 Indian rupees)
(Reporting by Chris Thomas in Bengaluru and Aftab Ahmed in New Delhi; Editing by Savio D'Souza)
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
